Physician profile
Muhammad Aziz
NPI 1437152873
$1,506.93
in general payments reported to CMS, 2019-2025
16 companies · $289 in 2025
The $289 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $173 · 2020: $113 · 2021: $217 · 2022: $216 · 2023: $282 · 2024: $218 · 2025: $289.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $789.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $788.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $601.23 | 2021-2025 | Ubrelvy, Qulipta, Vraylar |
| Pfizer INC. | $467.95 | 2019-2025 | |
| Sunovion Pharmaceuticals INC. | $104.74 | 2019-2021 | |
| Glaxosmithkline, LLC. | $74.71 | 2023-2024 | Trelegy Ellipta, Arexvy, Shingrix |
| Janssen Pharmaceuticals, INC | $49.05 | 2024 | Xarelto |
| Novo Nordisk INC | $46.89 | 2019-2025 | Ozempic, Rybelsus |
| Ortho-Clinical Diagnostics, INC. | $30.03 | 2019 | |
| Avanir Pharmaceuticals, INC. | $29.84 | 2019 | |
| Hologic Sales and Service, LLC | $27.50 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $16.81 | 2025 | Farxiga |
| Teva Pharmaceuticals USA, INC. | $16.57 | 2025 | Austedo Xr |
| Urovant Sciences INC | $14.24 | 2022 | |
| Si-Bone, INC. | $14.20 | 2019 | |
| Intercept Pharmaceuticals, INC. | $13.17 | 2019 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Muhammad Aziz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.